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Aims Kv7.4, a voltage-dependent potassium channel expressed throughout the vasculature, controls arterial contraction and
is compromised in hypertension by an unknown mechanism. MicroRNAs (miRs) are post-transcriptional regulators of
protein production and are altered in disease states such as hypertension. We investigated whether miRs regulate Kv7.4
expression.
Methods
and results
In renal and mesenteric arteries (MAs) of the spontaneously hypertensive rat (SHR), Kv7.4 protein decreased com-
pared with the normotensive (NT) rat without a decrease in KCNQ4 mRNA, inferring that Kv7.4 abundance was de-
termined by post-transcriptional regulation. In silico analysis of the 3′ UTR of KCNQ4 revealed seed sequences for
miR26a, miR133a, miR200b, miR153, miR214, miR218, and let-7d with quantitative polymerase chain reaction showing
miR153 increased in those arteries from SHRs that exhibited decreased Kv7.4 levels. Luciferase reporter assays indi-
cated a direct targeting effect of miR153 on the 3′ UTR of KCNQ4. Introduction of high levels of miR153 to MAs in-
creased vascular wall thickening and reduced Kv7.4 expression/Kv7 channel function compared with vessels receiving a
non-targeting miR, providing a proof of concept of Kv7.4 regulation by miR153.
Conclusion This study is the first to define a role for aberrant miR153 contributing to the hypertensive state through targeting of
KCNQ4 in an animal model of hypertension, raising the possibility of the use of miR153-related therapies in vascular
disease.
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1. Introduction
Primary hypertension is a major risk factor for cardiovascular disease
which continues to be the leading cause of death globally and is pre-
dicted to dominate mortality trends in the future.1 The hypertensive
state is precipitated by decreased luminal diameter brought about by
increased arterial contractility, lack of response to endogenous va-
sorelaxants, and vessel wall remodelling.2 – 5 Among the possible
modulators of arterial contractility, the Kv7 channels encoded by
KCNQ genes regulate vascular smooth muscle contractility in rodent
and human arterial beds, with Kv7.4 and Kv7.5 playing a key functional
role in regulating vascular tone directly and contributing to endogen-
ous vasodilatations.3,4,6 – 15 Recently, we discovered that Kv7.4 chan-
nel activity is down-regulated in aorta, mesenteric, renal, and
coronary arteries from spontaneously hypertensive rats (SHRs)
and mesenteric arteries (MAs) from angiotensin II-infused mice,
which was associated with a reduction in total Kv7.4 protein.3,4,6,7
Interestingly, only in aorta from SHRs was a reduction in KCNQ4
mRNA detected, and cerebral arteries from SHRs exhibit no Kv7 dys-
function.3,6,15 These observations suggest that Kv7.4 abundance is
determined by post-transcriptional mechanisms in an artery-specific
manner.
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MicroRNAs (miRs) are powerful post-transcriptional regulators of
gene expression.16,17 These small (20–25 nt) noncoding RNAs bind
to a target recognition site (‘seed sequence’) in the three prime un-
translated region (3′UTR) of mRNA transcripts leading to mRNA
degradation and/or inhibition/activation of protein translation depend-
ing on complementarity of the miR with the target mRNA.18,19 Several
studies have determined the importance of miRs in vascular smooth
muscle cell (VSMC) function in health and disease,20 – 23 but no study
has examined the impact of miRs on vascular Kv7.4. Since miRs
are heavily implicated in various vascular diseases and given the im-
portance of Kv7 channels in the vasculature, this study investigates
whether miRs have a regulatory role on Kv7.4 and identifies that
miR153 targets KCNQ4, which may contribute to vascular dysfunction
in hypertension.
2. Methods
Detailed experimental protocols are available in the Supplementary mater-
ial online.
2.1 Animals
Male normotensive (NT) Wistar rats and SHRs (Charles River, U.K.; 147+
6 mmHg—mean BP in a cohort of 12-week SHRs), 12–16 weeks of age
(175–225 g), were killed by cervical dislocation in accordance with the
UK Animal (Scientific Procedures) Act 1986. All animals were culled by
Schedule 1 methods, and therefore no approval from a local or university
ethics review board was required. This investigation conforms to Directive
2010/63/EU of the European Parliament on the protection of animals used
for scientific purposes.
2.2 In silico analysis for prediction of miR targets
Candidate miRs that potentially target the 3′UTR of KCNQ4 were identi-
fied using the established miR target prediction algorithm, TargetScan6.2
and mirDIP, a miR data integration portal.
2.3 Transfection of miR mimics into mesenteric
or middle cerebral arteries
Synthetic RNA molecules, miR153, miR133a, and non-targeting control
(NTC) miR (Active Motif, La Hulpe, Belgium), were designed to mimic en-
dogenous mature miR153, miR133a, or act as a NTC, respectively. NTC
miR has no known homology to human (or rat) gene sequences and acts
as a negative control. Whilst miR153 acts as a functional equivalent to en-
dogenous human miR153, the sequence is 100% conserved in rat. Twelve-
nanomolar miR153 (+ miR133a for cotransfection studies) or NTC miR
were transfected into mesenteric or middle cerebral arteries (MCAs)
from NT rats using TransIT-X2 and OptiMEMw I Reduced-Serum Medium
according to the manufacturer’s protocol (Mirus Bio LLC, Madison, USA).
Twenty-four hours post transfection, arteries were used in functional/stain-
ing studies or harvested for RNA or protein for quantitative polymerase
chain reaction (qPCR) or western blot, respectively.
2.4 Synthesis of KCNQ4 3′UTR luciferase
reporter, miR153 binding site mutants and
transfection into HEK293 cells
A fragment of the KCNQ4 mRNA 3′UTR (NM_0047000.3) containing 4
predicted binding sites for miR153 was synthesized and subcloned into
pLightSwitch_3′UTR luciferase expression reporter vector, downstream
of the Renilla luciferase reporter gene (GoClone), by SwitchGear Genom-
ics (Active Motif). Site-specific mutagenesis of two predicted miR153 bind-
ing sites was engineered in pLightSwitch-KCNQ4_3′UTR vector using the
QuikChange II site-directed mutagenesis kit (Agilent Technologies, CA,
USA) according to the manufacturer’s instructions. Deletion of seed
sequences corresponding to Site 1 (D Site 1, 8 nucleotides) and Site 4
(D Site 4, 7 nucleotides) was obtained using specific pairs of primers de-
signed using the online QuikChange Primer Design Program (www.
agilent.com/genomics/qcpd). Effective deletion of Site 1 and Site 4 regions
was verified by direct sequencing. The pLightSwitch_3′UTR luciferase
expression reporter vector containing no insert (EMPTY_3UTR, Active
Motif) was used as positive control for transfection to allow assay normal-
ization. The following groups were set up for transfection of HEK293 cells
using TransIT-X2: (i) WT KCNQ4 3′UTR + miR153, (ii) WT KCNQ4
3′UTR + NTC miR, (iii) D Site 1 KCNQ4 3′UTR + miR153, (iv) D Site 1
KCNQ4 3′UTR + NTC miR, (v) D Site 4 KCNQ4 3′UTR + miR153, (vi)
D Site 4 KCNQ4 3′UTR + NTC miR, (vii) WT KCNQ4 3′UTR, (viii) EMP-
TY_3′UTR, and (ix) TransIT-X2. Twenty-four hours post transfection,
luciferase activity was measured using the LightSwitch Assay Reagent kit
(LS010, Active Motif) designed for use with all GoClone reporter plasmids.
2.5 RNA extraction, reverse transcription, and
quantitative polymerase chain reaction
The miRNeasy Mini Kit (Qiagen, Manchester, UK) was used for effective
purification of miR and total RNA from dissected rat arteries. Samples
were reverse transcribed using the miScript II RT Kit (Qiagen) with HiFlex
buffer to allow miR as well as mRNA to be quantified from the same sam-
ple. Measurements of miR or mRNA levels were performed by qPCR using
the miScript SYBR Green PCR Kit (Qiagen) with the CFX96 real-time PCR
Detection System (Bio-Rad, Hertfordshire, UK).
2.6 Western blot
Artery protein lysates were probed after transfer to polyvinylidene fluoride
(PVDF) membrane (Millipore, Hertfordshire, UK) with a primary antibody
diluted in blocking buffer either overnight at 48C or for 1 h at room tem-
perature. Primary antibodies used were rabbit anti-Kv7.4 (1:200; sc-50417;
Santa Cruz, TX, USA) and mouse b-Actin (1:5000; A1978; Sigma Aldrich,
Dorset, UK).
2.7 Functional studies
Morphological properties of MAs from NT rats and SHRs as well as NT
MAs treated with NTC miR or miR153 were studied using Pressure Servo
System PS/200 (Living Systems Instrumentations, Burlington, VT, USA). The
structural properties of the segments and responses to the Kv7 activator,
S1 (NeuroSearch A/S, Ballerup, Denmark) were recorded and acquired
with DMK 41AU02 Monochrome Industrial Camera (Imaging Source,
Bremen, Germany) hosted by a PC running MyoVIEW II software (Danish
Myo Technology, Aarhus, Denmark). Data were analysed using MyoVIEW II
and MicroCal Origin 6.0 (MicroCal Software, Northampton, MA, USA).
Isometric tension was recorded on NT MAs or MCAs transfected with ei-
ther mir153 or NTC miR in a wire myograph (Danish Myo Technology).
Mesenteric vessels were pre-constricted with 1 mM U46619 (Sigma
Aldrich) and a concentration effect curve to the Kv7.2–7.5 activators
ML213 (HelloBio, Bristol, UK), ICA-069673 (HelloBio), the b-adrenoceptor
agonist isoprenaline (Sigma Aldrich), or the Kv7.1-specific activator RL-3
(Tocris, Bristol, UK) as well as a relaxation response to 1 mM nicardipine (Sig-
ma Aldrich) were obtained. Relaxant responses to S1 or ML213 were also
assessed in MCAs transfected with miR153 or NTC and pre-constricted
with 100 nM U46619. Data were recorded and analysed using LabChartw
7 (ADInstruments, Dunedin, New Zealand).
2.8 Histology
MA branches transfected with NTC miR or miR153 were embedded in
OCT, frozen rapidly, and cryosectioned at 7 mm. Slices were then fixed
with ice-cold acetone and stained using an Elastica van Gieson staining kit or
successively stained with haematoxylin and eosin (H&E; Merck, NJ, USA).
After dehydration, slices were covered with DPX mounting solution and
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stored for further use. An Axioplan 2 Upright microscope with attached
Axio Cam Digital CCD camera (Carl Zeiss Ltd, Cambridge, UK) was
used for imaging.
2.9 Statistical analysis
The data were expressed as mean+ SEM (standard error) with N repre-
senting the number of animals and n the number of experiments. Compar-
isons of data were accomplished by one-way or two-way ANOVA followed
by Bonferroni’s multiple comparisons test; Student’s t-test, or paired t-test
as appropriate. The differences between means were considered signifi-
cantly different when P, 0.05.
3. Results
3.1 Kv7.4 protein is down-regulated in
hypertensive arteries
Previous findings on Kv7.4/KCNQ4 arterial expression in hyperten-
sive animals have been obtained in different arteries in various separ-
ate studies.3,4,6,7,15 Initial experiments in the current study therefore
sought to corroborate these previous results but within one study to
allow novel comparisons to be made. Interrogation of protein lysates
from HEK293 cells stably expressing Kv7.4, with a Kv7.4 antibody
produced reactive bands corresponding to the theoretical molecular
weight of Kv7.4 that were not present in untransfected HEK293 cells
(n ¼ 3, Supplementary material online, Figure S1). Similar reactive
bands were identified in protein lysates from thoracic aortic arteries
(TAs), MAs, renal arteries (RAs) and MCAs from NT rats and SHRs
(Figure 1A). Kv7.4 expression was decreased in TAs (59.45+ 15.69%,
N ¼ 8, P ¼ 0.02), MAs (27.33+ 8.32%, N ¼ 8, P ¼ 0.04), and RAs
(36.14+ 11.96%, N ¼ 6, P ¼ 0.03) from SHRs compared with NT
rats (Figure 1B–D). In contrast, there was no difference in Kv7.4
protein expression in MCAs from SHR and NT animals (N ¼ 3,
P ¼ 0.21, Figure 1E).
QPCR was undertaken to assess whether the decrease of Kv7.4 pro-
tein in SHRs correlated to a reduction of KCNQ4 mRNA. In TAs from
SHRs, there was a 1.35-fold decrease in KCNQ4 mRNA expression
(N ¼ 4, P ¼ 0.03, Figure 1F), whereas for MAs, KCNQ4 mRNA in-
creased 13.35-fold (N ¼ 3, P ¼ 0.02, Figure 1G) in SHRs compared
with NT rats. There was no difference in mRNA levels between
SHRs and NT rats in RAs (N ¼ 4, P ¼ 0.29, Figure 1H) or MCAs
(N ¼ 3, P ¼ 0.17, Figure 1I). Overall, these data show that Kv7.4 is com-
promised in different arteries from SHRs that is not consistently asso-
ciated with a change in transcript level.
3.2 miR153 increases in SHR mesenteric,
renal, and thoracic aortic arteries compared
with NT rats
TargetScan6.2 and mirDIP were used to identify candidate miRs
targeted at the 3′UTR of KCNQ4 (Supplementary material online,
Figure S2). This analysis revealed putative seed sequences in KCNQ4
for miR26a, miR214, miR133a, miR200b, miR153, miR218, and let-7d.
Among them, miR153 showed the highest probability of consensus tar-
geting. Analogous miR153 seed sequences were not detected in the 3′
UTR of KCNQ5 or KCNQ1, the other KCNQs highly expressed in the
vasculature.8
Figure 1 Kv7.4 protein expression is decreased in SHR mesenteric, renal, and thoracic aortic arteries compared with NT rats with a decrease in
KCNQ4 expression in SHR thoracic aortic arteries compared with NT rats. (A) Representative western blot for Kv7.4 expression in total protein lysates
from NT rats and SHRs: TA, MA, RA, and MCA. b-Actin bands indicate protein loading controls. (B–E) Mean (+SEM) pixel densities of Kv7.4 bands
normalized to their respective b-actin bands for NT and SHR (B) TA, (C) MA, (D) RA, and (E) MCA from at least 3 separate protein isolations (N ¼ 3–8).
(F–I) QPCR analysis with 22DDCq of relative abundance of KCNQ4 of the SHR compared with the NT rat in (F) TA, (G) MA, (H) RA, and (I) MCA from at
least 3 separate RNA isolations (mean+ SEM, N ¼ 3–4). *P, 0.05 according to paired Student’s t-test.
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The working hypothesis is that an increase in miR expression in SHR
arteries results in Kv7.4 reduction. Figure 2 shows that whilst the
expression of miR26a, miR200b, miR214, miR218, and let-7d was
not altered in arteries from SHRs compared with NT, a significant in-
crease of miR153 was recorded in SHR MA (8.65, N ¼ 6, P, 0.0001),
RA (2.08, N ¼ 6, P , 0.0001), and TA (2.80, N ¼ 6, P , 0.0001).
A 1.35-fold increase was also observed for miR133a in SHR aorta
(N ¼ 6, P ¼ 0.006). Interestingly, miR153 was higher in the plasma
from SHRs compared with NT plasma (N ¼ 6, P ¼ 0.14, Supplemen-
tary material online, Figure S3). In contrast, there was no change in
the expression of any miRs in MCAs from SHRs compared with NT
rats (Figure 2D, N ¼ 5, all P-values were not significant). Consequently,
miR153 expression paralleled hypertension-induced changes in Kv7.4
levels across the arteries under study.
3.3 miR153 is confirmed to interact
functionally with KCNQ4 3′UTR
A luciferase reporter was engineered to contain a fragment of the
KCNQ4 mRNA 3′UTR encompassing 4 predicted binding sites for
miR153 (wild-type, WT); or deletion of seed sequences corresponding
to Site 1 (D Site 1) and Site 4 (D Site 4, Figure 3A). HEK293 cells cotrans-
fected with WT KCNQ4 3′UTR and miR153 produced a decrease in
luciferase activity compared with those cotransfected with KCNQ4
3′UTR and the non-targeting miR control (NTC miR, n ¼ 4, P, 0.01,
Figure 3B), which was eliminated when the 2 predicted binding sites
were deleted (D Site 1, n ¼ 3, P ¼ 0.72 and D Site 4, n ¼ 4, P ¼ 0.76);
indicating that miR153 interacts functionally with the 3′UTR of KCNQ4.
3.4 Addition of a synthetic miR153 to NT
mesenteric arteries mimics an SHR-like
phenotype
In all of the arteries studied, SHR MAs showed the greatest fold in-
crease in miR153 compared with NT rats; hence, we focused on
MAs from NT rats for our transfections studies with a miR153 mimic.
Addition of miR153 to MAs from NT rats resulted in a large increase in
miR153 levels compared with arteries from the same animal trans-
fected with NTC miR (N ¼ 11, P ¼ 0.04, Figure 4A). In arteries trans-
fected with miR153, KCNQ4 mRNA expression increased
approximately two-fold (N ¼ 4, P ¼ 0.02, Figure 4B), whilst Kv7.4 abun-
dance decreased by 75.43+ 0.15% (N ¼ 3, P, 0.0001, Figure 4C)
Figure 2 miR153 increases in SHR mesenteric, renal, and thoracic aortic arteries compared with NT rats. QPCR analysis with 22DDCq of relative abun-
dance of miR26a, miR214, miR133a, miR200b, miR153, miR218, and let-7d of the SHR compared with the NT rat in (A) MA, (B) RA, (C) TA, and (D) MCA
from at least 5 separate RNA isolations (mean+ SEM, N ¼ 5–6). ****P, 0.0001 and **P, 0.01 according to Student’s t-test.
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compared with NTC miR-transfected vessels, which mirrored the
changes recorded for SHRs shown in Figure 1. Cotransfection of NT
MAs with miR153 and miR133a showed a marked decrease of
KCNQ4 (N ¼ 4, P, 0.05, Supplementary material online, Figure S4A)
but not KCNQ5 (N ¼ 4, P ¼ 0.34, Supplementary material online,
Figure S4B), compared with NTC miR-transfected vessels.
Perfusion myograph experiments showed that transfection of MAs
from NT rats with miR153 produced morphological changes to the
Figure 4 Transfection of NT MAs with miR153 leads to up-regulation of KCNQ4 expression and down-regulation of Kv7.4 expression. QPCR analysis
with 22DDCq of relative abundance of (A) miR153 or (B) KCNQ4 in NT MAs transfected with non-targeting miR control (NTC) or miR153; data are
normalized to NTC-transfected NT MAs (mean+ SEM, N ¼ 11 and N ¼ 4, respectively). *P, 0.05 according to paired Student’s t-test. (Ci) Mean pixel
densities of Kv7.4 bands normalized to their respective b-actin bands for NT MAs transfected with NTC or miR153 from 3 separate protein isolations
(N ¼ 3). ****P, 0.0001 according to ratio paired t-test. (Cii) Representative western blot for Kv7.4 expression in total protein lysates from NT MAs
transfected with NTC or miR153. b-Actin bands indicate control for protein loading.
Figure 3 miR153 targets KCNQ4 3′UTR. (A) Schematic representation of human KCNQ4 mRNA 5′UTR, coding sequence, and 3′UTR with miR153
binding sites highlighted. Red, blue, light blue, and green squares in the 3′UTR indicate the predicted binding sites for miR153 (Sites 1, 2, 3, and 4, re-
spectively). Seed sequences corresponding to Site 1 (red), Site 2 (blue), Site 3 (light blue), and Site 4 (green) are highlighted in the grey boxes showing the
detailed nucleotide sequence of KCNQ4 3′UTR. Positions of the seed sequences are indicated above with the same colour scheme. (B) Mean luciferase
activity in HEK293 cells of KCNQ4 3′UTR WT, with deleted Site 1 (D Site 1), and with deleted Site 4 (D Site 4), co-transfected with miR153. Data are
normalized to HEK293 cells transfected with KCNQ4 3′UTR only and expressed as % of HEK293 cells transfected with the same plasmids in the pres-
ence of NTC (mean+ SEM, n ¼ 3–4). **P, 0.01 according to paired Student’s t-test (miR153 vs. NTC for each plasmid).
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artery that approximated a SHR-like phenotype (Figure 5A–C and Sup-
plementary material online, Tables S1 and S2, n ¼ 10–12; N ¼ 7–10).
In all experiments, arteries with similar outer wall dimensions were
used, and transfection with NTC miR had no effect on wall morphology
(Figure 5, Supplementary material online, Tables S1 and S2). However,
transfection with miR153 for 24 h produced a significant increase in the
media/lumen ratio that approached the values obtained in arteries from
SHRs (Figure 5A and B, Supplementary material online, Tables S1 and
S2). Average wall thickness was also enhanced in miR153-transfected
(31.0+ 1.0 mm) and SHR (37.0+ 1.4 mm) MAs compared with
NTC miR-transfected vessels (24.9+1.1 mm, P, 0.01) or NT vessels
(22.9+1.3 mm, P, 0.001), respectively (Figure 5A and C, Supplemen-
tary material online, Tables S1 and S2) with Figure 5Di indicating an in-
crease in the tunica media of miR153-transfected vessels compared with
the control but no increase in cell number (Figure 5Dii; 49+ 2 vs. 47+
3 nuclei per slice for NTC miR- or miR153-transfected NT MAs, re-
spectively, n ¼ 12–13, P ¼ 0.621). Consequently, a short-term in-
crease of miR153 in NT MAs produced morphological changes
analogous to arteries from SHRs.
In further perfusion myograph studies application of the Kv7
activator, S1 caused a decrease in the media/lumen ratio in NTC
miR-transfected NT vessels (0.162+ 0.013–0.125+ 0.013, N ¼ 4,
P, 0.01) but had no effect on miR153-transfected MAs (0.195+
0.012+ S1 vessels, N ¼ 4, P ¼ 0.391, Figure 6A). Isometric tension
recordings of these miR153-transfected vessels also showed decreased
relaxation to two structurally different Kv7 activators, ML21324 (N ¼ 8,
P, 0.01, Figure 6B), which was similarly lacking in arteries from
SHRs (N ¼ 3, P, 0.05 Figure 6B); and ICA673 (N ¼ 5, P, 0.0001
or P, 0.01, Figure 6C). A similar trend in the relaxation response
to the b-adrenoceptor agonist isoprenaline was also observed in
miR153-transfected MAs (N ¼ 6, P. 0.05, Figure 6D). Neither the re-
laxant effect of 1 mM nicardipine (86.98+ 0.68 vs. 90.53+ 2.68 for
NTC miR- or miR153-transfected NT MAs, respectively, N ¼ 4–5,
P ¼ 0.3) and the Kv7.1-specific activator, RL-325 (N ¼ 4–8, Sup-
plementary material online, Figure S5A) nor vessel constriction by the
thromboxane A2 analogue U46619 (N ¼ 4–8, Supplementary material
online, Figure S5B) was affected by miR153 over-expression. Conse-
quently, increasing miR153 levels exogenously to NT MA mimics
functional characteristics of MAs from SHRs. Interestingly, in cerebral
arteries where responses to Kv7.2–5 activators are unaffected
in SHRs15 and no rise in miR153 was detected, transfection with
exogenous miR153 produced a marked impairment in the relaxant
Figure 5 Addition of miR153 to MAs of NT rats leads to vascular wall thickening. (A) Examples of raw CCD camera images (left) and corresponding
automatic digitizing of outer and inner diameters (right) of native rat MA segments pressurized to 60 mmHg for NT MA, non-targeting miR control (NTC
miR)-transfected artery, miR153-transfected artery (miR153), and SHR MA. (B) Mean (+SEM) media/lumen ratios and (C) mean (+SEM) media thickness
of NTC miR compared with miR153-transfected NT MAs; and MAs of NT rats compared with SHRs (n ¼ 10–12; N ¼ 7–10). ***P, 0.001 or **P, 0.01
according to one-way ANOVA followed by Bonferroni’s multiple comparisons test. (D) Representative images of (i) Elastica van Gieson staining or (ii) H&E
staining (dark blue indicates nuclei, n ¼ 12–13) of NTC miR (left image) and miR153 (right image) transfected MA segments; scale bars: 35 mm.
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response to S1 and ML213 (N ¼ 4–5, P, 0.01 and P, 0.001, respect-
ively, Figure 6E).
4. Discussion
This study is the first to provide evidence for a role for miRs in the regu-
lation of Kv7.4 in the vasculature and raises the possibility that this
post-transcriptional regulation is a contributing factor of vascular dys-
function. As there is considerable evidence that Kv7 channels regulate
vascular smooth muscle contractility and contribute to the vasodilator
response of many endogenous agents,3,4,6– 15,24,26–28 the present study
implicates miR153 as a determinant of vascular tone and potentially a
novel therapeutic target for the treatment of hypertension.
In accordance with previous findings,3,4,7 we observed a decrease in
Kv7.4 protein expression in mesenteric and renal arteries from SHRs
that was not associated with a decrease of KCNQ4 mRNA. This sug-
gests that a post-transcriptional regulator, such as miRs, dictates Kv7.4
abundance. Indeed, the expression profile of miRs predicted to target
KCNQ4 revealed an up-regulation of miR153 in arteries from SHRs
compared with NT rats. Moreover, in cerebral arteries, where there
was no difference in Kv7.4 protein or mRNA expression between
NT and SHR and no change in Kv7 activity functionally,15 there was
no increase of miR153 or any of the miRs analysed. Hence, the
miR153 expression profile correlates closely with the Kv7.4/KCNQ4
expression profiles for the four arteries in hypertension. The reason
for this variability between arteries is difficult to define in detail since
the nature of cell-specific regulation by miRs continues to be investi-
gated, but it provides a mechanism to tailor cellular responses to indi-
vidual cell types. We propose that miR153 represses translation of
KCNQ4 mRNA rather than by transcript degradation as KCNQ4 le-
vels did not decrease in renal or MAs. In fact, KCNQ4 expression in-
creased markedly in MAs from SHRs or after miR153 transfection,
which is probably due to the suppression of a negative feedback loop
altering transcription factors.29 In aorta from SHRs, miR133a as well as
miR153 increased, but in this artery, the decreased Kv7.4 protein ex-
pression was associated with a decrease in mRNA. Interestingly, we re-
duced KCNQ4 transcript levels in NT MAs by co-transfecting miR153
with miR133a providing support for our hypothesis that in the aorta a
rise in miR133a affects KCNQ4 transcription, whereas the rise in
miR153 seen in the aorta, renal, and MAs leads to impaired translation
of KCNQ4 mRNA. Mir133a has been implicated in modulation of the
VSMC phenotype in general and specifically in the regulation of VSMC
proliferation in mouse aorta.23,30 However, as miR133a was unchanged
in other hypertensive vessels that displayed reduced Kv7.4 expression
and miR153 was consistently up-regulated in these vessels, we focused
on defining the impact of miR153 on Kv7.4 in hypertension.
Having identified a rise in miR153 expression correlated with a
reduction of Kv7.4, we established that miR153 has a direct targeting
Figure 6 Addition of miR153 to MAs or MCAs of NT rats leads to a reduced response to Kv7 activators. (A) Mean (+SEM) media/lumen ratios of
non-targeting miR control (NTC miR)-transfected NT MAs compared with S1-treated NTC miR-transfected vessels; and miR153-transfected MAs com-
pared with S1-treated miR153-transfected NT MAs (N ¼ 4). (B) Mean (+SEM) percentage relaxation to 1 mM ML213 from isometric tension record-
ings in NTC miR compared with miR153-transfected NT MAs; and in MAs of NT (NT MA) rats compared with SHR MA (N ¼ 3–8). *P, 0.05 and
**P, 0.01 according to one-way ANOVA followed by Bonferroni’s multiple comparisons test. Isometric tension recordings of relaxation to increasing
concentrations of (C) the Kv7 activator ICA-069673, (D) the b-adrenoceptor agonist isoprenaline in NT MAs transfected with miR153 or NTC miR. Each
point represents the mean of 4–8 animals+ SEM. ****P, 0.0001 and **P, 0.01 according to two-way ANOVA followed by Bonferroni’s multiple
comparisons test. (E) Mean (+SEM) percentage relaxation to 100 nM S1 or 100 nM ML213 from isometric tension recordings in NTC miR compared
with miR153-transfected NT MCAs (N ¼ 4–5). ***P, 0.001 and **P, 0.01 according to two-way ANOVA followed by Bonferroni’s multiple com-
parisons test.
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effect on the 3′UTR of KCNQ4 using a luciferase reporter assay. Fur-
thermore, we showed that addition of synthetic miR153 to MAs from
NT rats caused an up-regulation of KCNQ4 mRNA, decreased Kv7.4
protein expression, and attenuated relaxations to structurally different
Kv7 activators similar to that seen in arteries from SHRs (current study
and3,4,7,15). A shift in the relaxation response to the b-adrenoceptor
agonist isoprenaline was also observed in miR153-transfected MAs al-
though not significantly, which may reflect the complex intracellular sig-
nalling involved. Interestingly, transfection of miR153 impaired the
relaxation induced by Kv7 activators in the cerebral artery, which
showed no change in miR153 levels between NT and hypertensive
rats, further suggesting that a rise in miR153 down-regulates Kv7.4 pro-
tein function. It is worth stressing that the rise in miR153 produced by
transfection with a synthetic mimetic far exceeds levels seen in arteries
from SHRs. However, we have no knowledge about the regulation of
miR153 in arteries in response to hypertensive cues, and the data are a
good proof of concept. The striking similarity in Kv7 characteristics be-
tween arteries from SHRs and those from NT rats transfected with
miR153 provides strong support for miR153 regulation of Kv7.4. Fur-
thermore, it is possible that in SHRs, miRs exert their effect in a time-
dependent manner. Thus, to obtain a similar effect in our in vitro system,
after only 24 h, we need a very high concentration of miR153.
Remarkably, our pressure myography data showed that media/lu-
men ratio and average wall thickness were significantly increased in
miR153-transfected vessels compared with NTC miR-transfected ves-
sels, showing a tendency of shifting the morphological characteristics of
native NT MAs towards an SHR phenotype within 24 h after transfec-
tion. The increase in average wall thickness (from 24.9+ 1.1 to 31.0+
1.0 mm) produced by miR153 transfection is equivalent to the possible
appearance of just one extra layer of smooth muscle cells. Vascular re-
modelling31,32 involves several cell types including a phenotypic switch
of VSMCs between a differentiated, contractile state with a low prolif-
eration rate to a dedifferentiated, synthetic state in which VSMCs are
more proliferative.33,34 Studies with vascular smooth muscle-specific
knockout of Dicer show miRs are crucial for VSMC development, dif-
ferentiation, and contractile function.20 –22,35 Importantly, widespread
loss of miR expression in these knockout animals caused decreased
blood pressure attributed to a reduced contractile tone and media
thickness in aorta.36 miR153 has also been linked to proliferation in
venous samples after mechanical injury.37 However, H&E staining did
not reveal an increase in cell number in the tunica media, suggesting
that the wall thickening stems from deposition of collagen, fibronectin,
and other components of the extracellular matrix similar to the remod-
elled arterial structures in SHRs31,32 or there is an increase in cell size.
The mechanisms linking Kv7.4 dysfunction and changes in arterial
morphology and responsiveness will be the focus of future studies.
It should be emphasized that miR153-induced KCNQ4 down-
regulation is only a contributory component in the multifactorial dis-
ease of hypertension. miR153 is known to affect targets other than
KCNQ4,37– 40 although TargetScan6.2 predicted miR153 to only target
the 3′UTR of KCNQ4 and not KCNQ5 or KCNQ1, the other KCNQs
highly expressed in the vasculature. Moreover, KCNQ1 and KCNQ5
are down-regulated by other miRs, namely, miR1/133 and miR190, re-
spectively.41,42 Nevertheless, the parallel change in miR153 and Kv7.4 is
clear raising the possibility that correction of the miR153 up-regulation
that leads to the aberrant Kv7 channel function/expression, vaso-
constriction, and vascular wall thickening, through the use of miR
sponges,43 chemical inhibitors,44 and antagomirs45 as a potential treat-
ment for hypertension. Furthermore, a rise of miR153 was detected in
the blood of SHRs, suggesting that this may present a novel diagnostic
marker for hypertensive scenarios. However, investigation of antago-
miRs on ex vivo arteries from SHRs should be approached with caution
since we have preliminary data indicating that a ‘loss’ of the SHR pheno-
type occurs in arteries incubated in Dulbecco’s modified Eagle’s me-
dium (DMEM) for 24–72 h (Supplementary material online, Figure
S6A–C ). Interestingly, we observed a decreased trend of miR153 in
MAs from SHR upon incubation in DMEM for 48 h, possibly explaining
the loss of Kv7.4 functional impairment observed in the incubated ves-
sels (Supplementary material online, Figure S6D).
Increased vascular tone, a relative resistance to vasorelaxants and
vascular remodelling underlie vascular disease. Our data define a role
for aberrant miR153 underlying this hypertensive state through target-
ing of KCNQ4 in an animal model of hypertension. Research into vas-
cular Kv7 channels is in its infancy, and therefore it is not possible at the
moment to determine how much regulation of Kv7.4 channels by miRs
contributes to post-transcriptional control globally. Further research is
required to determine the full spectrum of miR153 target genes, pos-
sible side effects, and a therapeutic strategy/delivery for the correction
of miR153 up-regulation, but the potential use of miR153-related ther-
apies in clinical vascular disease is certainly worth exploring further.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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